Targeting Mitochondrial Dysfunction
Our lead product, Imeglimin, is in Phase 3 development in Japan and has successfully completed Phase 2 development in the U.S. and EU.
View Candidate
Innovative Pipeline of First-In-Class Products
Our candidates are based on disease-modifying mechanisms of action that offer the potential for safer and more effective therapies for type 2 diabetes and NASH.
View Pipeline
Backed by Strong Leadership
Our highly-experienced clinical and regulatory teams possess the know-how and experience to successfully develop products within our pipeline.
Meet Our Team
Latest News
Poxel Reports Financial Results for the First Half 2018 and Provides Corporate Update
Executed strategic agreement for Imeglimin with Roivant Sciences, which included USD 35 million upfront payment, and potential for up to USD 600 million in regulatory and development milestone payments and…
Read this Press Release: Poxel Reports Financial Results for the First Half 2018 and Provides Corporate UpdatePoxel Appoints Takashi Kaneko, MD, PhD, as Senior Vice President Medical and President of Poxel Japan K.K
Poxel has also established a Japanese subsidiary in Tokyo Both events are strategic commitments to the Japanese and Asian markets Lyon, France, September 13, 2018 – POXEL SA (Euronext – POXEL -…
Read this Press Release: Poxel Appoints Takashi Kaneko, MD, PhD, as Senior Vice President Medical and President of Poxel Japan K.KPoxel Announces Participation at the H.C. Wainwright 20th Annual Global Investment Conference
LYON, France--(BUSINESS WIRE)--POXEL S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes…
Read this Press Release: Poxel Announces Participation at the H.C. Wainwright 20th Annual Global Investment Conference
